Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + bevacizumab with or without tiragolumab in untreated advanced hepatocellular carcinoma
jRCT2021230021Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Atezolizumab + bevacizumab + tiragolumab with Atezolizumab + bevacizumab + placebo (2 arms). Primary endpoint: Primary efficacy (RECIST v1.1). Started Oct 2023; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2021230021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230021.